Randomized Trial of Intracoronary Adenosine As Adjunctive Therapy for Prevention of the No-Reflow Phenomenon Publisher Pubmed



Naghshtabrizi N¹ ; Sajedi M² ; Naghshtabrizi B³ ; Mozayanimonfared A³ ; Ali Seif Rabiei M⁴ ; Kanonisabet A⁵
Source: Coronary Artery Disease Published:2020

Abstract

No-reflow phenomenon as a serious complication following percutaneous coronary intervention, deteriorates clinical outcomes. Intracoronary (IC) Adenosine, seems to be a way to deal with it. One hundred four consecutive patients with ST-segment elevation myocardial infarction were randomized into two groups. Each group consisted of 52 patients who managed with two bolus doses of IC Adenosine (Adenosine group) or two bolus doses of IC normal saline (placebo group) administered before and after stenting. Thrombolysis in myocardial infarction (TIMI) grade flow, ST-segment resolution (STR) and post-procedural clinical outcomes were used as endpoints. IC adenosine led to lower rates of no-reflow based on TIMI grade flow scaling (15.4% vs. 44.3%; P-value: 0.02). STR classified as complete, partial and no resolution was similar between two groups (P-value: 0.748). Also, post-interventional clinical outcomes, including arrhythmia, left ventricular ejection fraction, hospitalization time, and 30 days mortality were similar between Adenosine and placebo groups. © 2020 Lippincott Williams and Wilkins. All rights reserved.